Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions

IMPORTANCE: Low- and middle-income countries have a high burden of respiratory syncytial virus lower respiratory tract infections. A monoclonal antibody administered monthly is licensed to prevent these infections, but it is cost-prohibitive for most low- and middle-income countries. Long-acting mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Laufer, Rachel S., Driscoll, Amanda J., Baral, Ranju, Buchwald, Andrea G., Campbell, James D., Coulibaly, Flanon, Diallo, Fatoumata, Doumbia, Moussa, Galvani, Alison P., Haidara, Fadima C., Kotloff, Karen L., Keita, Adama M., Neuzil, Kathleen M., Orenstein, Evan W., Orenstein, Lauren A.V., Pecenka, Clint, Sow, Samba, Tapia, Milagritos D., Ortiz, Justin R., Fitzpatrick, Meagan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377743/
https://www.ncbi.nlm.nih.gov/pubmed/34325934
http://dx.doi.org/10.1016/j.vaccine.2021.06.086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377743/
https://www.ncbi.nlm.nih.gov/pubmed/34325934
http://dx.doi.org/10.1016/j.vaccine.2021.06.086

Ejemplares similares